Log In
Print
BCIQ
Print
Print this Print this
 

trenonacog alfa (Ixinity) (IB1001)

  Manage Alerts
Collapse Summary General Information
Company Emergent BioSolutions Inc.
DescriptionRecombinant coagulation Factor IX (rFIX)
Molecular Target Factor IX
Mechanism of ActionFactor IX replacement
Therapeutic ModalityBiologic
Latest Stage of DevelopmentApproved
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding in patients with hemophilia B; Treat bleeding associated with hemophilia B
Regulatory Designation

U.S. - Undisclosed Review (Treat and prevent bleeding in patients with hemophilia B)

Partner

Ipsen Group


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$55.9M

$5.9M

$50.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today